• Publications
  • Influence
Gene expression during normal and FSHD myogenesis
BackgroundFacioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, thatExpand
  • 83
  • 6
Early de novo DNA methylation and prolonged demethylation in the muscle lineage
Myogenic cell cultures derived from muscle biopsies are excellent models for human cell differentiation. We report the first comprehensive analysis of myogenesis-specific DNA hyper- andExpand
  • 68
  • 3
Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
BACKGROUND The BRAF-V600E mutation is associated with tumor aggressiveness and poor prognosis in melanoma patients. Identification of this mutation is clinically important as we now have Food andExpand
  • 31
  • 2
Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo.
Although overall survival rate for patients with thyroid cancer (TC) is high, there is an alarming 10-year recurrence rate of up to 30% conferring a ~50% survival among these high-risk patients. TheExpand
  • 7
  • 1
  • PDF
Prognostic Role of BRAFV600E Cellular Localization in Melanoma.
BACKGROUND Approximately half of cutaneous melanoma tissues harbor BRAFV600E mutations, resulting in a constitutive activation of the mitogen-activated protein kinase (MAPK) pathway.Expand
  • 9
  • 1
DNA methylation and differentiation: HOX genes in muscle cells
BackgroundTight regulation of homeobox genes is essential for vertebrate development. In a study of genome-wide differential methylation, we recently found that homeobox genes, including those in theExpand
  • 43
Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.
The MAP kinase and NF-κB signaling pathways play an important role in thyroid cancer tumorigenesis. We aimed to examine the therapeutic potential of dually targeting the two pathways using AZD6244Expand
  • 19
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
BACKGROUND Although a wide spectrum of inhibitors of the MEK/ERK and PI3K/AKT pathways have been discovered and entered clinical trials, the effects of their individual use in thyroid cancer wereExpand
  • 30
Immunohistochemistry as an accurate tool for evaluating BRAF‐V600E mutation in 130 samples of papillary thyroid cancer
Background. BRAFV600E mutation has been investigated by immunohistochemistry and has shown high sensitivity and specificity. We aim to investigate the accuracy of immunohistochemistry versusExpand
  • 21
Stem cell biology in thyroid cancer: Insights for novel therapies.
Currently, thyroid cancer is one of the most common endocrine cancer in the United States. A recent involvement of sub-population of stem cells, cancer stem cells, has been proposed in differentExpand
  • 10